Pronethalol ((±)-Pronethalo) is a non-selective β-adrenergic antagonist. Pronethalol is a potent inhibitor of Sox2 expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias and limits the cerebral arteriovenous malformation (AVMs).

Product information

CAS Number: 54-80-8

Molecular Weight: 229.32

Formula: C15H19NO

Synonym:

(±)-Pronethalo

Chemical Name: 1-(naphthalen-2-yl)-2-[(propan-2-yl)amino]ethan-1-ol

Smiles: CC(C)NCC(O)C1=CC=C2C=CC=CC2=C1

InChiKey: HRSANNODOVBCST-UHFFFAOYSA-N

InChi: InChI=1S/C15H19NO/c1-11(2)16-10-15(17)14-8-7-12-5-3-4-6-13(12)9-14/h3-9,11,15-17H,10H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 50 mg/mL (218.04 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Pronethalol (2, 10, 20 μM) represses EGFP expression in a dose- and time-dependent manner in ReNcell VM cells. Pronethalol (10 μM; 2 days) reduces Sox2 expression to less than 10% after 2 days of treatment.

In Vivo:

Pronethalol (0.15 mg/g; daily; for 14 days) stabilizes endothelial differentiation, lumen formation and improves cerebral arteriovenous malformation (AVMs) in Mgp–/– mice.

References:

1. Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71(4):503-508.
2. Jiayi Yao, et al. Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations. J Clin Invest. 2019 Jun 24;129(8):3121-3133.

Products are for research use only. Not for human use.